HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast

  HeartWare Presentation at Leerink Swann Global Healthcare Conference to be
                                   Webcast

PR Newswire

FRAMINGHAM, Mass. and SYDNEY, Feb. 8, 2013

FRAMINGHAM, Mass. and SYDNEY, Feb. 8, 2013 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less
invasive, miniaturized circulatory support technologies that are
revolutionizing the treatment of advanced heart failure, today announced that
CEO Doug Godshall is scheduled to present at the Leerink Swann Global
Healthcare Conference at 8:30 a.m. Eastern Standard Time on Wednesday,
February 13, 2013. The conference is being held February 13-14 at the
Waldorf-Astoria in New York.

A live webcast of the Company's presentation at the conference will be
available via a link provided at www.heartware.com. A replay of the webcast
will be available for 90 days at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable
heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure. The HeartWare^® Ventricular Assist
System features the HVAD^® pump, a small full-support circulatory assist
device designed to be implanted next to the heart, avoiding the abdominal
surgery generally required to implant competing devices. The HeartWare System
is approved in the United States for the intended use as a bridge to cardiac
transplantation in patients who are at risk of death from refractory end-stage
left ventricular heart failure, and has received CE Marking in the European
Union and has been used to treat patients in 27 international countries. The
device is also currently the subject of a U.S. clinical trial for destination
therapy. For additional information, please visit the Company's website at
www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000^® and its
securities are publicly traded on The NASDAQ Stock Market and the Australian
Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of
HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.

Website: http://www.heartware.com
 
Press spacebar to pause and continue. Press esc to stop.